Faculty Bibliography

Premenopausal women who present with acute pelvic pain frequently pose a diagnostic dilemma, exhibiting nonspecific signs and symptoms, the most common being nausea, vomiting, and leukocytosis. Diagnostic considerations encompass multiple organ systems, including obstetric, gynecologic, urologic, gastrointestinal, and vascular etiologies. The selection of imaging modality is determined by the clinically suspected differential diagnosis. Thus, a careful evaluation of such a patient should be performed and diagnostic considerations narrowed before a modality is chosen. Transvaginal and transabdominal pelvic sonography is the modality of choice when an obstetric or gynecologic abnormality is suspected, and computed tomography is more useful when gastrointestinal or genitourinary pathology is more likely. Magnetic resonance imaging, when available in the acute setting, is favored over computed tomography for assessing pregnant patients for nongynecologic etiologies because of the lack of ionizing radiation

Recently, applications for subspecialty fellowship positions in obstetrics and gynecology have increased dramatically. A survey completed by fellows in Maternal-Fetal Medicine (MFM), Reproductive Endocrinology (REI), Gynecologic Oncology (Gyn Onc), and Urogynecology (Urogyn) training programs in the United States between January and March 2006 was aimed at determining why this trend was occuring. Of 449 fellows in 2006, 192 (42.8%) responded. The two most influential factors in all four subspecialties were interest and lifestyle (P < .001). Although these factors were similar throughout all subspecialties, variations exist in how fellows rated each factor by subspecialty. An overwhelming majority (99%) of fellows were either "very satisfied" or "satisfied" with their decisions to pursue fellowship training. The majority of fellows believe that when compared to a generalist Obstetrician/Gynecologist (OB/GYN) they will have a reduced workload, decreased liability, and a higher salary. The recent increase in the number of fellowship applicants is most likely due to a complex interplay of multiple factors.

OBJECTIVE: To compare maternal and neonatal outcomes of pregestational and gestational diabetics treated with insulin glargine versus Neutral Protamine Hagedorn (NPH) insulin. METHODS: A retrospective cohort study examining outcomes from pregestational and gestational diabetics treated with either insulin regimen. Comparisons were made using the t-test for continuous data and the Chi-square or Fisher's exact test for categorical data. RESULTS: Fifty-two pregnant women treated with insulin glargine were compared with 60 pregnant women treated with NPH. No significant differences in rates of maternal complications were noted. No significant differences in neonatal outcomes for gestational diabetics were noted. Among pregestational diabetics treated with insulin glargine, significantly fewer macrosomic infants (relative risk [RR], 0.38; 95% confidence intervals (CI), 0.17-0.87; p = 0.04) and lower rates of neonatal hyperbilirubinemia (RR, 0.27; 95% CI, 0.07-0.98; p = 0.05) were noted when compared with those treated with NPH. There were no cases of neonatal hypoglycemia in pregestational diabetics treated with glargine; however, 25% of infants born to mothers treated with NPH experienced hypoglycemia (p = 0.01). No fetal anomalies or deaths were observed in either treatment group. CONCLUSION: Insulin glargine use during pregnancy is not associated with increased maternal or neonatal morbidity compared with NPH insulin. Among pregestational diabetics, insulin glargine use was associated with lower rates of macrosomia, neonatal hypoglycemia and neonatal hyperbilirubinemia.

New insight into the pharmacological mechanisms of acetaminophen raises questions about its possible safety in certain subgroups of pregnant women. Recent focus on acetaminophen's ability to modulate prostaglandin synthesis may require modification of its ubiquitous use in pregnancy. Further basic science, epidemiologic and clinical studies are required to explore the interaction of acetaminophen with placentation leading to vascular pathologic conditions during pregnancy.

OBJECTIVE: To quantify the risk for symptomatic uterine rupture during a trial of labor after prior cesarean delivery based on factors that can be ascertained during early pregnancy. METHODS: From all trials of labor over a 12-year period, we determined those factors associated with an increased or decreased risk for uterine rupture and assigned scores. The following numerical scores were used: 2 points for > or = 2 prior cesarean scars, 1 point for interdelivery interval < or = 18 months, 1 point for maternal age of 30-39 years, 2 points for maternal age > or = 40 years, minus 1 point for women with prior vaginal delivery and one prior cesarean. RESULTS: There were 40 uterine ruptures in 4383 trials of labor (0.91%). Overall, the rate of uterine rupture varied by score: -1-0.26% (1/391), 0-0.25% (4/1613), 1-1.11% (21/1894), 2-2.43% (9/370), 3-3.70% (4/108), and 4-14.29% (1/7), p = .001. CONCLUSIONS: The rate of symptomatic uterine rupture during a trial of labor varies greatly depending on easily identified risk factors, and is low for women without risk factors.

OBJECTIVE: The purpose of this study was to evaluate stepwise sequential screening for fetal aneuploidy. STUDY DESIGN: Women who received first-trimester screening were also offered second-trimester tests with second-trimester risks that were based on both sets of markers. Screen-positive rates, use of second-trimester testing and invasive testing, sensitivity, and changes in risks were evaluated. RESULTS: Of 1528 women who received first-trimester screening, 133 women (8.7%) had an indication for invasive testing that was based on first-trimester results alone; 1173 women (76.8%) received second-trimester tests, which reduced the net number of women with an indication for invasive testing to 105 (6.9%). In unaffected pregnancies, the addition of the second-trimester testing reduced the median Down syndrome risk from 1:2368 to 1:10,301. Six of 10 chromosome abnormalities (60%) were identified by first-trimester screening, and 9 of 10 chromosome abnormalities (90%) were identified by sequential screening. CONCLUSION: Sequential screening can be introduced successfully into clinical practice, is effective, and can reduce the number of invasive tests that are performed.

OBJECTIVE: To estimate the accuracy of evaluating nasal bone length, expressed as multiples of the median (MoM), for the detection of Down syndrome in second- trimester fetuses. METHODS: Expected normal median nasal bone measurements were established for an initial cohort of women receiving fetal ultrasound examinations at 15-24 weeks of gestation. Nasal bone lengths were converted to MoM with adjustment for maternal race and ethnicity using whites as the referent group. Nasal bone MoM were compared in euploid and Down syndrome fetuses. The sensitivity and specificity were evaluated in this initial cohort and in a second cohort in which all ultrasound measurements were carried out prospectively. RESULTS: For the combined data set, 10 of 21 affected pregnancies had an absence of the nasal bone (sensitivity 47.6%), but absence was noted in only 1 of 2,515 unaffected pregnancies (false-positive rate 0.04%). Using less than 0.80 MoM as a cutoff, the sensitivity was 20 of 21 (95.2%), and the false-positive rate was 185 of 2,515 (7.4%). Changing the cutoff to 0.75 MoM resulted in 18 of 21 (85.7%) sensitivity and 74 of 2,515 (2.9%) false-positive rate. Using medians derived from whites to calculate MoM for the entire population resulted in higher false-positive rates. CONCLUSION: Nasal bone length expressed as MoM seems to be an useful ultrasound marker for Down syndrome in second-trimester fetuses with a high sensitivity and a low false-positive rate. LEVEL OF EVIDENCE: III.

OBJECTIVE: The purpose of this study was to determine the influence of race and ethnicity on the expected nasal bone length (NBL) based on biparietal diameter (BPD) measured in second-trimester fetuses. METHODS: We searched our ultrasound, obstetric, and cytogenetic databases for all second-trimester fetuses with measured NBLs. Fetuses with Down syndrome were identified and excluded from the analysis. Linear regression curves were generated for NBL by BPD according to race and ethnicity. Categories used were African American, Hispanic, Asian, and white. Analysis of variance was used to compare mean variation of observed from expected NBL by BPD according to race and ethnicity. RESULTS: There were 717 fetuses with NBL-by-BPD pairs who were available for analysis in our population, including 139 African American, 58 Hispanic, 22 Asian, and 498 white fetuses. Nasal bone length was highly correlated with BPD for each race (P < .001). Mean variances of observed from expected NBL by BPD were statistically different according to race or ethnicity (P = .0092). CONCLUSIONS: Race and ethnicity significantly affect the mean regression line of expected NBL by BPD among fetuses in the second trimester. Genetic sonographic norms, therefore, appear to require race- and ethnicity-specific formulas for NBL.

OBJECTIVE: To determine the frequency of echogenic intracardiac focus (EIF) by race/ethnicity. METHODS: We performed a retrospective analysis from January 1996 through June 2003. We reviewed all initial sonograms from 14 to 23 weeks gestation in singleton pregnancies. Mothers on admission for delivery provided race/ethnicity. RESULTS: There were 8207 ultrasounds and deliveries that met study criteria. There were 4636 (56.5%) Caucasian, 2087 (25.4%) African-American, 1261 (15.4%) Hispanic and 223 (2.7 %) Asian subjects. There were 347 (4.2%) EIF detected. The frequency by race/ethnicity varied significantly (p < 0.0001). CONCLUSIONS: This large, population-based study showed that fetuses born to Asian mothers were significantly more likely to have an EIF. This racial difference should be taken into account when counseling patients about the potential for Down syndrome.